Mark Cuban Cost Plus Drug Company (MCCPDC) announced it partnered with PharmcoRx Pharmacy, a Florida-based health service organization Progressive Care subsidiary, and tech-enabled Expion Health’s to lower drug prices for consumers.
PharmcoRx has become a participating pharmacy in MCCPDC’s Team Cuban Card, allowing patients at PharmcoRx locations access generic and brand-name medications at MCCPDC prices.
PharmcoRx will also market the program to its existing customers and network of local clinics and care practices.
Through the Expion Health partnership, the tech-enabled company will integrate MCCPDC’s drug prices into its product suite to lower the cost of specialty drugs.
“By teaming up with Cost Plus Drugs, we’re amplifying our sourcing capabilities and deepening transparency in pharmacy cost management. This collaboration echoes our ambition to explore diverse pricing pathways and offer better cost options for consumers,” Karin Humphrey, chief executive officer of Expion Health, said in a statement.
THE LARGER TREND
In February, MCCPDC announced its Team Cuban Card program via Twitter, which aims to create an independent pharmacist network. The company boasts that the program is now available in select independent and grocery pharmacies in 46 states and Washington, D.C.
This year has been exceptionally fruitful for MCCPDC in that it announced a myriad of partnerships.
The company collaborated with multinational pharmaceutical company Lupin Limited, the COPD Foundation, Salt Lake City-based Select Health and Coherus Biosciences to sell Yusimry, a biosimilar version of the top-selling drug Humira.
The company also partnered with Latino care virtual healthcare service Zócalo Health, Tennessee-based RxPreferred Benefits, California-based EmsanaRx, diabetes and chronic disease management company Diathrive Health and cancer care support company OncoPower.
Last year, MCCPDC announced its first health plan partnership with Capital Blue Cross, in which Capital members could use their insurance cards at MCCPDC directly.